Literature DB >> 28994001

Comparison Between Etest and Broth Microdilution Methods for Testing Itraconazole-Resistant Aspergillus fumigatus Susceptibility to Antifungal Combinations.

Laura Bedin Denardi1,2, Jéssica Tairine Keller3,4, Maria Isabel de Azevedo5,4, Vanessa Oliveira4, Fernanda Baldissera Piasentin3,4, Cecília Bittencourt Severo6, Janio Morais Santurio5,4, Sydney Hartz Alves3,4.   

Abstract

The checkerboard broth microdilution assay (BMD) is the most frequently used method for the in vitro evaluation of drug combinations. However, its use to evaluate the effect of antifungal drugs on filamentous fungi is sometimes associated with endpoint-reading difficulties, and different degrees of interaction are assigned to the same drug combination. We evaluated combinations of the azoles, itraconazole, posaconazole, and voriconazole, with the echinocandins, anidulafungin, caspofungin, and micafungin, against 15 itraconazole-resistant Aspergillus fumigatus clinical strains via the checkerboard BMD and Etest assay. Readings after 24 and 48 h, considering the two reading endpoints, the minimum inhibitory concentration (MIC) and minimum effective concentration (MEC), were performed for both methods. Our results showed that the correlation coefficients between the BMD and Etest methods were quite diverse to the drug combinations tested. The highest correlation coefficients of the Etest with the BMD assays (MEC and MIC reading) were the Etest-MIC reading at 24 h and the Etest-MEC reading at 48 h. Improvements in experimental conditions may increase the correlation between the two methods and ensure that Etest assay can be safely used in the evaluation of antifungal combinations against Aspergillus species.

Entities:  

Keywords:  Antifungal combinations; Aspergillus fumigatus; Broth microdilution; Etest

Mesh:

Substances:

Year:  2017        PMID: 28994001     DOI: 10.1007/s11046-017-0208-7

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  42 in total

1.  [Successful treatment of invasive sinus aspergillosis with micafungin and itraconazole].

Authors:  Masaki Okamoto; Teruhisa Azuma; Hiroyasu Ishimaru; Noriyuki Abe; Masaru Komatsu; Kazuhiro Hatta
Journal:  Kansenshogaku Zasshi       Date:  2006-03

2.  Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Guillermo Garcia-Effron; Laura Alcazar-Fuoli; Emilia Mellado; Maria J Buitrago; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro.

Authors:  Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  J Antimicrob Chemother       Date:  2005-09-27       Impact factor: 5.790

4.  Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.

Authors:  Antigoni Elefanti; Johan W Mouton; Paul E Verweij; Athanassios Tsakris; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

5.  Epidemiology of visceral mycoses in autopsy cases in Japan: the data from 1989 to 2009 in the Annual of Pathological Autopsy Cases in Japan.

Authors:  Yuhko Suzuki; Hikaru Kume; Tomiteru Togano; Yuhsaku Kanoh; Hitoshi Ohto
Journal:  Med Mycol       Date:  2013-01-17       Impact factor: 4.076

6.  Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration.

Authors:  Jeff Fuller; Adam Schofield; Safeer Jiwa; Crystal Sand; Brad Jansen; Robert Rennie
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

7.  Activity of antifungal combinations against Aspergillus species evaluated by isothermal microcalorimetry.

Authors:  Ulrika Furustrand Tafin; Christina Orasch; Andrej Trampuz
Journal:  Diagn Microbiol Infect Dis       Date:  2013-07-19       Impact factor: 2.803

8.  Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Willem J G Melchers; Antonius J M M Rijs; Paul E Verweij; Johan W Mouton
Journal:  J Antimicrob Chemother       Date:  2012-11-05       Impact factor: 5.790

9.  In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.

Authors:  Seyedmojtaba Seyedmousavi; Joseph Meletiadis; Willem J G Melchers; Antonius J M M Rijs; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

10.  Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism.

Authors:  Eveline Snelders; Henrich A L van der Lee; Judith Kuijpers; Anthonius J M M Rijs; János Varga; Robert A Samson; Emilia Mellado; A Rogier T Donders; Willem J G Melchers; Paul E Verweij
Journal:  PLoS Med       Date:  2008-11-11       Impact factor: 11.069

View more
  3 in total

1.  Comparison of the MICs Obtained by Gradient Concentration Strip and EUCAST Methods for Four Azole Drugs and Amphotericin B against Azole-Susceptible and -Resistant Aspergillus Section Fumigati Clinical Isolates.

Authors:  S Dellière; L Verdurme; J Bigot; E Dannaoui; Y Senghor; F Botterel; A Fekkar; M E Bougnoux; C Hennequin; J Guitard
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 2.  Antifungal Susceptibly Testing by Concentration Gradient Strip Etest Method for Fungal Isolates: A Review.

Authors:  Eric Dannaoui; Ana Espinel-Ingroff
Journal:  J Fungi (Basel)       Date:  2019-11-22

Review 3.  Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations.

Authors:  Anne-Laure Bidaud; Patrick Schwarz; Guillaume Herbreteau; Eric Dannaoui
Journal:  J Fungi (Basel)       Date:  2021-02-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.